Clinical Trial

Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

Study acronym: IC19 CAR-T
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is an open label, single arm exploratory clinical trial of IC19 CAR-T cell therapy for refractory systemic lupus erythematosus. Patients who are still in an active state after systemic treatment using the standard treatment regimen specified in the treatment guidelines were selected to receive IC19 CAR-T cell single pulse infusion therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-14.
Trial Details
NCT Number NCT06886919
Lead Sponsor Beijing Immunochina Medical Science & Technology Co., Ltd.
Conditions Difficult to Treat Systemic Lupus Erythematosus
Enrollment 6 participants
Start Date 2025-03-31
Primary Completion 2025-09-30 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-24